|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Treatment |  |  |  |  |  |
| Patient | Age | Sex | HLA | Histology | Surg | Chemo | Rad | Metastasis | Stage | OS (month) | Positive well | CTL frequency |
| B01 | 74 | M | A\*24:02/\*02:03 | ADC | + | + | - | lung, mediastinum | IV | 98 | 3/24 | 3.0×10-6 |
| B02 | 70 | M | A\*24:02/\*02:06 | ADC | - | - | + | bone | IV | 23 | 1/24 | 4.4×10-7 |
| B03 | 59 | M | A\*24:02/unknown | ADC | - | + | - | lymph node, brain | IV | >118 | 2/24 | 5.6×10-7 |
| B04 | 98 | F | A\*24:02/\*02:06 | ADC | - | - | - | - | II | >33 | 1/24 | 2.3×10-6 |
| B05 | 60 | F | A\*24:02/\*02:01 | ADC | - | + | - | lung, liver | IV | 44 | 0/24 | <2.0×10-7 |
| B06 | 71 | F | A\*24:02/\*02:01 | ADC | + | + | + | bone, brain | IV | >120 | 3/24 | 4.1×10-6 |

Supplementary Table 2

\* ADC, adenocarcinoma; Surg, surgery; Chemo, chemotherapy; Rad, radiotherapy; OS, overall survival (a sign of inequality indicates the patient was alive as of Apr 1st, 2017); Positive well, number of IV9-HLA-A24 tetramer-positive wells (>0.02% positivity); CTL frequency, frequency of IV9-HLA-A24 tetramer-positive CTLs (=number of positive wells/(24 × initial number of CD8-positive cells per well)